OPERATING SEGMENT (Details) |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Sep. 30, 2024
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Sep. 30, 2025
USD ($)
segment
|
Sep. 30, 2024
USD ($)
|
|
| SEGMENT INFORMATION | ||||||||
| Number of operating segments | segment | 1 | |||||||
| Number of reportable segments | segment | 1 | |||||||
| Research and development: | ||||||||
| General and administrative | $ 2,327,391 | $ 7,834,181 | $ 8,949,015 | $ 19,105,853 | ||||
| Segment and consolidated net loss | 4,443,877 | $ 5,447,911 | $ 6,604,029 | 14,664,719 | $ 919,371 | $ 26,641,983 | 16,495,816 | 42,226,073 |
| Single reportable segment | ||||||||
| Research and development: | ||||||||
| Phase 2 study in B-cell malignancies, including WM and MM | 143,000 | 742,000 | 1,245,000 | 5,726,000 | ||||
| Phase 1 study in pediatric tumors | 225,000 | 769,000 | 1,175,000 | 2,428,000 | ||||
| Phase 1 study in triple negative breast cancer | 214,000 | 265,000 | ||||||
| Manufacturing and related costs | 1,195,000 | 2,469,000 | 2,776,000 | 8,410,000 | ||||
| Pre-clinical projects costs | 72,000 | 49,000 | 724,000 | 101,000 | ||||
| General research and development costs | 674,000 | 1,465,000 | 2,155,000 | 3,262,000 | ||||
| General and administrative | 2,327,000 | 7,834,000 | 8,949,000 | 19,106,000 | ||||
| Other segment items | (406,000) | 1,337,000 | (793,000) | 3,193,000 | ||||
| Segment and consolidated net loss | $ 4,444,000 | $ 14,665,000 | $ 16,496,000 | $ 42,226,000 | ||||
| Other segment items, description | Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. | Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. | Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. | Other segment items consist of warrant issuance expense, (gain) loss on valuation of warrants, and interest income. | ||||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the direct costs of manufacturing and related costs. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the direct costs of Phase 1 study in pediatric tumors. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the direct costs of Phase 1 study in triple negative breast cancer. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the direct costs of Phase 2 study in B-cell malignancies, including WM and MM. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the indirect general research and development costs . No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the indirect pre-clinical projects costs. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|